Fleming Christopher, Morrissey Samantha, Cai Yihua, Yan Jun
Department of Medicine, Tumor Immunobiology Program, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.
Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, KY, USA.
Trends Cancer. 2017 Aug;3(8):561-570. doi: 10.1016/j.trecan.2017.06.003. Epub 2017 Jul 17.
Accumulating evidence suggests a role for gamma delta (γδ) T cells as unexpected drivers of tumor development and progression. These protumoral γδ T cells are abundant in the tumor microenvironment in both mouse and human. They promote tumor progression by: (i) inducing an immunosuppressive tumor microenvironment and angiogenesis via cytokine production; (ii) functioning as regulatory T (Treg)/T helper 2 (Th2)-like cells; (iii) interfering with dendritic cell (DC) effector function; and (iv) inhibiting antitumor adaptive T cell immunity via the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) pathway. Understanding how these cells are regulated and what their specific role in cancer is will provide insight for the development of approaches that specifically target these cells and can thereby improve the efficacy of cancer immunotherapies.
越来越多的证据表明，γδ T细胞作为肿瘤发生和进展的意外驱动因素发挥着作用。这些促肿瘤γδ T细胞在小鼠和人类的肿瘤微环境中都很丰富。它们通过以下方式促进肿瘤进展：(i) 通过产生细胞因子诱导免疫抑制性肿瘤微环境和血管生成；(ii) 发挥调节性T (Treg)/辅助性T 2 (Th2) 样细胞的作用；(iii) 干扰树突状细胞 (DC) 的效应功能；以及 (iv) 通过程序性死亡-1 (PD-1)-程序性死亡配体-1 (PD-L1) 途径抑制抗肿瘤适应性T细胞免疫。了解这些细胞是如何被调节的以及它们在癌症中的具体作用，将为开发特异性靶向这些细胞的方法提供思路，从而提高癌症免疫疗法的疗效。
